DCTH

#3150
Delcath Systems Inc
10.9900 USD
+1.01%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
10.9900
10.9900
1年のレンジ
8.1200
11.1500
1日の変化
+1.01%
月次変化
+11.35%
6か月変化
+6.29%
1年の変化
+6.29%
以前の終値
10.8800
始値
10.9900
Bid
Ask
安値
10.9900
High
10.9900
ボリューム
40
チャート全体を表示

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 381.8606 M
  • Employee 156
  • Founded 1988
  • CEO Gerard Michel
  • Website www.delcath.com
  • Headquarter Delaware, United States
  • FIGI BBG000BY2VF5
  • Industry 医療機器
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
144.29
売上高対価格比率
4.73

Delcath Systems Inc

Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally.

ニュース